Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Colorcon
Baxter
McKesson
Mallinckrodt

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Docket   Start Trial Date Filed 2017-06-26
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Defendant Referred To
Parties ACCORD HEALTHCARE INC.; ALKEM LABORATORIES LTD.; AMNEAL PHARMACEUTICALS LLC; AUROBINDO PHARMA U.S.A., INC.; AUROBINDO PHARMA USA LLC; BIOGEN INTERNATIONAL GMBH; BIOGEN MA INC.; CARIBE HOLDINGS (CAYMAN) CO. LTD.; CIPLA LIMITED; CIPLA USA INC.; DBA PURACAP CARIBE; GLENMARK PHARMACEUTICALS INC. USA; GLENMARK PHARMACEUTICALS LIMITED; GRAVITI PHARMACEUTICALS INC.; GRAVITI PHARMACEUTICALS PVT. LTD.; HETERO LABS LIMITED; HETERO LABS LIMITED UNIT-III; HETERO USA INC.; IMPAX LABORATORIES INC.; IMPAX LABORATORIES LLC; LUPIN ATLANTIS HOLDINGS SA; MACLEODS PHARMA USA, INC.; MACLEODS PHARMACEUTICALS LTD.; MSN LABORATORIES PRIVATE LTD.; MSN PHARMACEUTICALS INC.; PHARMATHEN S.A.; PRINSTON PHARMACEUTICAL INC.; PURACAP INTERNATIONAL LLC; S&B PHARMA, INC.; SANDOZ INC.; SAWAI PHARMACEUTICAL CO., LTD.; SAWAI USA INC.; SHILPA MEDICARE LIMITED; SLAYBACK PHARMA INDIA LLP; SLAYBACK PHARMA LLC; SUN PHARMA GLOBAL FZE; TEVA PHARMACEUTICALS USA INC.; TORRENT PHARMA INC.; TORRENT PHARMACEUTICALS LTD.; TWI PHARMACEUTICALS INC.; TWI PHARMACEUTICALS USA INC.; WINDLAS HEALTHCARE PVT. LTD.; ZYDUS PHARMACEUTICALS (USA) INC.
Patents 6,509,376; 7,320,999; 7,619,001; 7,803,840; 8,399,514; 8,759,393
Attorneys Aaron F. Barkoff; Adam Wyatt Poff; Alan Tenenbaum; Alejandro Menchaca; Alison M. Hill; Andrew Colin Mayo; Andrew E. Renison; Andy J. Miller; Anne Shea Gaza; Arthur G. Connolly , III; Benjamin J. Schladweiler; Bindu Ann George Palapura; Brian Sodikoff; Christopher B. Ferenc; Christopher M. Bruno; Christopher P. Galligan; David A. Bilson; David Ellis Moore; Dominick T. Gattuso; Don J. Mizerk; Dustin L. Taylor; Emily N. Winfield; Eric J. Fues; Erin M. Forbes; Erin R. Conway; Eve H. Ormerod; Frank D. Rodriguez; Frederick R. Ball; Gary Ji; George C. Lombardi; George J. Barry , III; Huiya Wu; Imron T. Aly; James B. Monroe; James P. Barabas; James S. Green , Jr.; Jeanette M. Roorda; Jeffer Ali; Jing Xia; John C. Phillips , Jr.; John R. McNair; Jonathan B. Turpin; Joseph E. Cwik; Joseph M. Reisman; Jovial Wong; Kelly E. Farnan; Kenton M. Walker; Kevin E. Warner; Li Feng; Loni L. Morrow; Mark Rubinshtein; Matthew M. Holub; Michael J. Gaertner; Michelle A. Herrera; Naomi L. Birbach; Neal C. Belgam; Patrick C. Gallagher; Paul W. Browning; Philip D. Segrest; Philip Y. Braginsky; Pilar Gabrielle Kraman; Rachel P. Waldron; Rajendra A. Chiplunkar; Richard L. Renck; Samantha G. Wilson; Samuel Sherry; Sanya Sukduang; Sara E. Bussiere; Saukshmya Trichi; Scott B. Feder; Shailendra K. Maheshwari; Stamatios Stamoulis; Stephen B. Brauerman; Steven J. Balick; Steven J. Moore; Thomas H. Ehrich; Thomas P. Krzeminski; Timothy F. Peterson; Timothy H. Kratz; Todd S. Werner; Vincent L. Capuano; William A. Rakoczy; William R. Zimmerman; Yun Wei
Firms Bayard, P.A.; Connolly Gallagher LLP; Duane Morris, LLP; Greenberg Traurig, the Nemours Building; Heyman Enerio Gattuso & Hirzel LLP; Phillips, Goldman, McLaughlin & Hall, P.A.; Smith, Katzenstein, & Jenkins LLP; Stamoulis & Weinblatt LLC; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Biogen International GmbH v. Amneal Pharmaceuticals LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the…regarding the ’376 patent, the ’999 patent, the ’001 patent, the ’840 patent and the ’514 patent, has a substantial…“the ’999 patent”), 7,619,001 (“the ’001 patent”), 7,803,840 (“the ’840 patent”) and 8,399,514 (“the …the ’514 patent”) arising under the patent laws of the United States, Title 35, United States Code, §§ … FIRST COUNT FOR PATENT INFRINGEMENT (’376 PATENT) 23. Biogen realleges External link to document
0000-00-00 121 Notice of Service U.S. Patent No. 6,509,376; and (2) Zydus's Initial Invalidity Contentions Regarding U.S. Patent 6,509,376… 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 166 Stipulation of Dismissal infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,5148,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 236 Opinion - Memorandum Opinion alleging infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the… 514 patent") (collectively, "patents-in-suit" or "asserted patents"). …;the ' 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the '…#39; 840 patent"), 8,759,393 ("the ' 393 patent"), and 8,399,514 ("the ' 514…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the External link to document
0000-00-00 292 Notice of Service Pharmaceutical Inc.'s Infringement of U.S.Patent No. 8,399,514; (2) Opening Expert Report of Robert O. …Pharmaceutical Inc.'s Infringement of U.S. Patent No. 8,399,514; (3) Opening Expert Report of Daniel R. …Pharmaceuticals Inc.'s Infringement of U.S. Patent No. 8,399,514; (4) Opening Expert Report of Robert O. …Pharmaceuticals Inc.'s Infringement of U.S. Patent No. 8,399,514; (5) Opening Expert Report of Daniel R. …Pharmaceutical Co., Ltd.'s Infringement of U.S. Patent No. 8,399,514; (6) Opening Expert Report of Robert O. External link to document
2019-11-08 326 Stipulation-General (See Motion List for Stipulation to Extend Time) -4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted…Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug …WHEREAS claims 5, 7, 14, and 17-20 of the Asserted Patent have not been asserted; WHEREAS, Zydus…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid or would not be infringed by the commercial… 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
Express Scripts
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.